Veloxis Pharmaceuticals Inc. and Sun Pharmaceutical Industries Ltd. reached a deal ending their patent suit and blocking a proposed generic version of Envarsus XR until May 2028.
Veloxis, a unit of Asahi Kasei Corp., and Sun agreed to dismiss the case and enter a consent judgment resolvingpatent claims over Sun’s proposed generic tacrolimus, Envarsus XR’s active ingredient, according to filings Judge Maryellen Noreika approved in orders issued Monday in the US District Court for the District of Delaware.
The agreement, which scuttled a bench trial that had been slated for this week over Envarsus XR, extended-release tablets used to ...
